Domain Therapeutics

OverviewSuggest Edit

Domain Therapeutics is a biopharmaceutical company. It uses transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.

TypePrivate
Founded2001
HQIllkirch-Graffenstaden, FR
Websitedomaintherapeutics.com

Latest Updates

Employees (est.) (Sept 2021)79
Cybersecurity ratingAMore

Key People/Management at Domain Therapeutics

Youssef L. Bennani

Youssef L. Bennani

Chairman
Pascal Neuville

Pascal Neuville

Chief Executive Officer, Director
Michel Ronc

Michel Ronc

Non-Executive Director
Stephan Schann

Stephan Schann

Director of Research & Development
Bernard Daugeras

Bernard Daugeras

Non-Executive Director
Marjorie Sidhoum

Marjorie Sidhoum

Director of Business Operations
Show more

Domain Therapeutics Office Locations

Domain Therapeutics has offices in Illkirch-Graffenstaden and Montréal
Illkirch-Graffenstaden, FR (HQ)
Bioparc 3, 850 boulevard Sébastien Brant
Montréal, CA
7171 Rue Frederick Banting, Saint-Laurent
Show all (2)

Domain Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2001

Domain Therapeutics total Funding

$41.5 m

Domain Therapeutics latest funding size

$3.91 m

Time since last funding

2 years ago

Domain Therapeutics investors

Domain Therapeutics's latest funding round in May 2019 was reported to be $3.9 m. In total, Domain Therapeutics has raised $41.5 m
Show all financial metrics

Domain Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Domain Therapeutics Online and Social Media Presence

Embed Graph

Domain Therapeutics Blogs

Discovery on Target 2021 : Domain Therapeutics to present its latest developments and research

Domain Therapeutics, a leading biopharmaceutical company focused on GPCR in immuno-oncology, is delighted to take part in the Discovery on Target 2021. Do not miss this chance to stay on top of our latest developments and research ! Stay tuned for more !     The post Discovery on Target 2021 : Domai…

SLAS Europe 2021 : Domain Therapeutics to present a poster about its powerful BRET-based platform dedicated to the study of immune checkpoint co-receptors.

  Domain Therapeutics, a leading GPCR company in the field of immuno-oncology is glad to participate next week to SLAS Europe digital conference. We are eager to share our latest poster with you and share more about Domain Therapeutics’ powerful BRET-based platform dedicated to the study of immune c…

Domain Therapeutics to sponsor IRIC’s Virtual Symposium : GPCRs In Oncology & Immuno-oncology

GPCRs constitute the largest family of human membrane proteins and play a critical role in fundamental physiological and pathological processes. With approximately one-third of marketed drugs targeting GPCRs, the ability of this family of receptors to be used as therapeutics is unmatched. However, t…

ASPET annual meeting 2021 : Domain Therapeutics to present its poster selected as a Program Committee Blue Ribbon Pick

The ASPET Annual Meeting at ExpBio is already next week ! Don’t miss Domain’s presentation of its poster selected by the ASPET program committee for a blue ribbon (Abstract ID #: R1694) ! Our expert will give you an inspiring illustration of how the proprietary platform bioSens-All® supported the pr…

Bloom Burton & Co. Healthcare Investor Conference 2021 : Pascal Neuville, CEO of Domain Therapeutics, to present our latest advances !

Don’t miss Domain Therapeutics CEO, Pascal Neuville’s presentation at the Bloom Burton & Co. Healthcare Investor conference on Tuesday April 20, 3:30 pm ET, to learn more about the latest advances at Domain Therapeutics, a preclinical-stage biopharmaceutical company discovering and developing in…

Domain Therapeutics presents most recent developments of its BRET technology portfolio at AACR and ASPET event

Presented posters highlight novel BRET-based assays to characterize RTK and ICP targets and reveal extensive profiling of signaling signature of 100 GPCRs   Strasbourg, France, April 08, 2021 – Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drug…
Show more

Domain Therapeutics Frequently Asked Questions

  • When was Domain Therapeutics founded?

    Domain Therapeutics was founded in 2001.

  • Who are Domain Therapeutics key executives?

    Domain Therapeutics's key executives are Youssef L. Bennani, Pascal Neuville and Michel Ronc.

  • How many employees does Domain Therapeutics have?

    Domain Therapeutics has 79 employees.

  • Who are Domain Therapeutics competitors?

    Competitors of Domain Therapeutics include Redesign Science, e-therapeutics and Innoforce Pharmaceuticals.

  • Where is Domain Therapeutics headquarters?

    Domain Therapeutics headquarters is located at Bioparc 3, 850 boulevard Sébastien Brant, Illkirch-Graffenstaden.

  • Where are Domain Therapeutics offices?

    Domain Therapeutics has offices in Illkirch-Graffenstaden and Montréal.

  • How many offices does Domain Therapeutics have?

    Domain Therapeutics has 2 offices.